Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have prostate cancer that has spread to other parts of the body, confirmed by CT scan, MRI, and/or bone scan (even if those spread areas are no longer visible on scans after starting hormone therapy, as long as they were visible before hormone therapy began).
• People who are 18 years of age or older at the time of signing the consent form.
• People whose general physical functioning falls within a certain range on a standard medical scale (from fully active to capable of limited self-care) (confirm with trial site).
• People in Cohort 1 who have hormone-sensitive prostate cancer that has spread, and who are planning to receive, are currently receiving, or have recently completed chemotherapy — with or without an additional hormone-blocking medication — and who started chemotherapy within roughly 30 weeks and hormone therapy within roughly one year before joining the trial.
• People in Cohort 2 who have hormone-sensitive prostate cancer that has spread, and who are planning to receive hormone therapy alone or with an additional hormone-blocking medication (but not chemotherapy), and who started that additional hormone-blocking medication within roughly 30 weeks and hormone therapy within roughly one year before joining the trial.
• People whose white blood cell count, infection-fighting cell count, and platelet count meet the minimum levels required before joining (support medications and transfusions are allowed to help meet these levels).
• People who are able to lie flat and still for about 15 to 20 minutes and can undergo a specialised PET/CT scan and radiation planning and treatment.
• People who have had or currently have another type of cancer, as long as the treating doctor considers that cancer unlikely to interfere with the study results or with receiving standard prostate cancer treatment for two years — and as long as any scan findings can still be clearly linked to prostate cancer.
• People who are expected to live for at least six months, in the opinion of the treating doctor.
• People who are able to understand and willing to sign a consent form before joining — including those who have an authorised representative or carer who can assist with this process.

Who may not be able to join:

• People whose prostate cancer has become resistant to hormone therapy, defined as having two rising PSA test results in a row even when testosterone levels are very low.
• People who started hormone therapy (such as injections or tablets that reduce testosterone, or who had surgical removal of the testes) more than approximately one year before joining the trial (note: a specific tablet called bicalutamide 50 mg daily is not counted as hormone therapy for this purpose).
• People who started additional treatments beyond basic hormone therapy — such as stronger hormone-blocking medications or chemotherapy — more than approximately 30 weeks before joining the trial (note: bicalutamide is not counted as an additional treatment for this purpose).
• People who have a known allergy to imaging contrast dye or a medical reason they cannot have a PET/CT scan — though people with a contrast allergy may still be considered eligible if their past reactions were not severe and they are willing and able to receive pre-medications according to standard hospital practice (confirm with trial site).
• People who are already enrolled in another clinical treatment trial that would conflict with participation in this trial.

Important: Always verify eligibility with the trial site directly before applying.